Literature DB >> 9262172

Comparative effects of a melatonin agonist on the circadian system in mice and Syrian hamsters.

O Van Reeth1, E Olivares, Y Zhang, P C Zee, E Mocaer, R Defrance, F W Turek.   

Abstract

S-20098 has potent and specific agonist properties on melatonin receptors both in vitro and in vivo. Behavioral studies on rodents already showed that repeated intraperitoneal administration of S-20098 could dose-dependently alter the functioning of the circadian clock. To determine whether single administration of S-20098 could alter the circadian rhythms of rodents, we first used the phase-response curve (PRC) approach in two different species: Syrian hamsters and mice (C3H/HeJ). Our results show that the shape, circadian times and extent of the PRC to S-20098 look very similar in mice and hamsters. In both species, the phase advance portion of the PRC to S-20098 is limited to a 3 h window preceding the onset of locomotor activity, but the magnitude of phase shifts is larger in mice. We also tested the phase shifting effects of increasing doses of S-20098 during the interval of maximal sensitivity to this compound. Treatment with S-20098 induces dose-dependent phase shifts, with maximal shifts observed after injections of 20 and 25 mg/kg S-20098 i.p., respectively, in mice and hamsters. Those results are in agreement with the limited distribution of melatonin-binding sites within the circadian clock of adult Syrian hamsters, as compared to other rodents.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9262172     DOI: 10.1016/s0006-8993(97)00382-x

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  15 in total

Review 1.  Circadian rhythms and mood regulation: insights from pre-clinical models.

Authors:  Colleen A McClung
Journal:  Eur Neuropsychopharmacol       Date:  2011-08-11       Impact factor: 4.600

2.  Circadian periods of sensitivity for ramelteon on the onset of running-wheel activity and the peak of suprachiasmatic nucleus neuronal firing rhythms in C3H/HeN mice.

Authors:  Oliver Rawashdeh; Randall L Hudson; Iwona Stepien; Margarita L Dubocovich
Journal:  Chronobiol Int       Date:  2011-02       Impact factor: 2.877

3.  Evaluation of serotonin, noradrenaline and dopamine reuptake inhibitors on light-induced phase advances in hamster circadian activity rhythms.

Authors:  Robert L Gannon; Mark J Millan
Journal:  Psychopharmacology (Berl)       Date:  2007-08-13       Impact factor: 4.530

Review 4.  Pressed for time: the circadian clock and hypertension.

Authors:  R Daniel Rudic; David J Fulton
Journal:  J Appl Physiol (1985)       Date:  2009-08-13

5.  Agomelatine treatment corrects impaired sleep-wake cycle and sleep architecture and increases MT1 receptor as well as BDNF expression in the hippocampus during the subjective light phase of rats exposed to chronic constant light.

Authors:  Jana Tchekalarova; Lidia Kortenska; Natasha Ivanova; Milena Atanasova; Pencho Marinov
Journal:  Psychopharmacology (Berl)       Date:  2019-11-13       Impact factor: 4.530

Review 6.  Agomelatine, the first melatonergic antidepressant: discovery, characterization and development.

Authors:  Christian de Bodinat; Béatrice Guardiola-Lemaitre; Elisabeth Mocaër; Pierre Renard; Carmen Muñoz; Mark J Millan
Journal:  Nat Rev Drug Discov       Date:  2010-06-25       Impact factor: 84.694

7.  Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors.

Authors:  Michel Bourin; Elisabeth Mocaër; Roger Porsolt
Journal:  J Psychiatry Neurosci       Date:  2004-03       Impact factor: 6.186

8.  Chronic agomelatine treatment corrects behavioral, cellular, and biochemical abnormalities induced by prenatal stress in rats.

Authors:  Sara Morley-Fletcher; Jerome Mairesse; Amelie Soumier; Mounira Banasr; Francesca Fagioli; Cecilia Gabriel; Elisabeth Mocaer; Annie Daszuta; Bruce McEwen; Ferdinando Nicoletti; Stefania Maccari
Journal:  Psychopharmacology (Berl)       Date:  2011-04-19       Impact factor: 4.530

9.  Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep-wake cycle architecture.

Authors:  Amandine Descamps; Colette Rousset; Mark J Millan; Mark Millan; Michael Spedding; Philippe Delagrange; Raymond Cespuglio
Journal:  Psychopharmacology (Berl)       Date:  2009-04-16       Impact factor: 4.530

10.  Agomelatine(S 20098) antagonizes the penile erections induced by the stimulation of 5-HT2C receptors in Wistar rats.

Authors:  Abdeslam Chagraoui; Philippe Protais; Thierry Filloux; Elisabeth Mocaër
Journal:  Psychopharmacology (Berl)       Date:  2003-08-07       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.